BRIEF published on 04/03/2025 at 13:24, 9 months 27 days ago Innate Pharma participates in the Stifel 2025 Virtual Targeted Oncology Forum Euronext Paris Oncology Immunotherapy Innate Pharma Virtual Forum
BRIEF published on 04/03/2025 at 13:18, 9 months 27 days ago Innate Pharma to Engage in Stifel 2025 Virtual Oncology Forum Biotechnology Immunotherapy Virtual Event Innate Pharma Oncology Forum 2025
PRESS RELEASE published on 04/03/2025 at 13:13, 9 months 27 days ago INSIDE INFORMATION / OTHER NEWS RELEASES Innate Pharma to participate in 2025 Stifel Virtual Targeted Oncology Forum. Executive team presenting and hosting 1x1 meetings. Focus on innovative cancer immunotherapies Cancer Innate Pharma Immunothérapies Stifel Targeted Oncology Forum
PRESS RELEASE published on 03/28/2025 at 14:37, 10 months 3 days ago Annual financial and audit reports / Annual financial report
BRIEF published on 03/20/2025 at 07:05, 10 months 12 days ago Innate Pharma Announces 2024 Financial Results Conference Financial Results Conference Call Stock Market Listing Cancer Immunotherapy Innate Pharma
PRESS RELEASE published on 03/20/2025 at 07:00, 10 months 12 days ago Inside Information / Other news releases Innate Pharma to hold conference call and webcast for full year 2024 financial results on March 27, 2025. Details for participation provided Financial Results Conference Call Biotechnology Webcast Innate Pharma
BRIEF published on 02/17/2025 at 07:07, 11 months 12 days ago Innate Pharma Receives Breakthrough Therapy Designation from FDA FDA Innate Pharma Breakthrough Therapy Lacutamab Sézary Syndrome
PRESS RELEASE published on 02/17/2025 at 07:02, 11 months 12 days ago Inside Information / Other news releases Innate Pharma receives U.S. FDA Breakthrough Therapy Designation for Lacutamab in Sézary syndrome treatment, showing promising results in Phase 2 TELLOMAK study FDA Innate Pharma Lacutamab Sézary Syndrome Breakthrough Therapy Designation
BRIEF published on 01/27/2025 at 07:05, 1 year ago Innate Pharma Initiates Phase 1 Study of IPH4502 for Advanced Solid Tumors Phase 1 Trial Innate Pharma IPH4502 Nectin-4 Advanced Solid Tumors
PRESS RELEASE published on 01/27/2025 at 07:00, 1 year ago Inside Information / Other news releases Innate Pharma announces first patient dosed in Phase 1 study of Nectin-4 targeting Antibody Drug IPH4502 in advanced solid tumors. Innovative ADC for multiple cancer types Innate Pharma Phase 1 Study IPH4502 Topoisomerase I Inhibitor Antibody Drug Conjugate
Published on 01/31/2026 at 03:15, 1 day 4 hours ago Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 01:40, 1 day 6 hours ago Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/30/2026 at 23:00, 1 day 9 hours ago Avidian Gold Corp. Announces Director Resignation
Published on 01/31/2026 at 15:54, 16 hours 17 minutes ago EQS-Adhoc: Wolford AG: Capital increase will not be implemented
Published on 01/31/2026 at 12:25, 19 hours 47 minutes ago JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 1 day 5 hours ago CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 1 day 10 hours ago Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 1 day 12 hours ago Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026
Published on 01/30/2026 at 17:45, 1 day 14 hours ago Schneider Electric launches a capital increase reserved for employees
Published on 01/29/2026 at 18:00, 2 days 14 hours ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 2 days 14 hours ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 2 days 14 hours ago Cegedim generated LFL revenue growth of 1.1% in 2025
